Key result
Dose-adjusted warfarin therapy reduces stroke risk in atrial fibrillation by 68%, yet many high-risk patients are not receiving anticoagulation due to insufficient use of risk stratification.
Why the study?
Does dose-adjusted warfarin therapy reduce stroke risk in older patients with atrial fibrillation?
Does dose-adjusted warfarin therapy reduce stroke risk in older patients with atrial fibrillation?
Despite the known efficacy of warfarin in reducing stroke risk by 68% in atrial fibrillation, risk stratification is underutilized and many high-risk older patients remain untreated.
Answers are grounded in this paper and cite their sources.
Highlights underuse of risk stratification in high-risk AF; hypothesis-generating for strategies to increase anticoagulation in older patients.
Meta-analyses of randomized controlled trials have reported the efficacy of dose-adjusted warfarin therapy (target International Normalised Ratio (INR) 2–3) in reducing stroke risk in atrial fibrillation by 68%, with aspirin reducing relative risk by 22%. Absolute benefit for an individual patient depends on the presence of the risk factors for stroke; these include previous stroke, transient ischaemic attack, hypertension, diabetes, valvular heart disease, heart failure and advanced age. In spite of reported benefit, many people with atrial fibrillation and a high risk of stroke are not receiving anticoagulation: disappointingly, risk stratification is not being sufficiently used to guide treatment.
No takes yet. Share an insight, caveat, or question.
Wynne et al. (2005) conducted a review in Atrial fibrillation. Dose-adjusted warfarin therapy was evaluated on Stroke risk (68% reduction). Dose-adjusted warfarin therapy reduces stroke risk in atrial fibrillation by 68%, yet many high-risk patients are not receiving anticoagulation due to insufficient use of risk stratification.
Synapse has enriched 10 related papers. Consider them for comparative context: